ClinicalTrials.gg
Sign In

Signs and Symptoms, Respiratory clinical trials

The registry lists 64 studies for Signs and Symptoms, Respiratory across more than 10 countries. 9 are recruiting or about to start. 19 of them are mainly about Signs and Symptoms, Respiratory (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27. Counting its 28 narrower conditions too, such as Sleep Apnea, Obstructive: 6,717 studies, 1,332 open.

Get an email when these change. Save the Signs and Symptoms, Respiratory studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
45
Active, not recruiting
5
Recruiting
5
Not yet recruiting
4
Status unknown
3
Terminated
1

Phase

Phase 3
6
Phase 2
3
Phase 1
1
Phase 4
1

Where

United States
17
France
7
Canada
6
Belgium
6
Korea, Republic of
6
Israel
5

Who runs them

Carmel Medical Center (3) · Bellus Health Inc. - a GSK company (2) · University of Sao Paulo (2) · Federal University of São Paulo (2) · ImThera Medical, Inc. (2) · Kazakhstan Academy of Preventive Medicine (2) · Cargill (2) · Merck Sharp & Dohme LLC (2)

Who develops what

Every programme with a company-led study here in the last two years, whatever its size: 1 programme from 1 company, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 programme — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. Phase 4 trial recorded: a phase 4 study exists somewhere; approval here is not checked. Not read yet: approvals and labels, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Signs and Symptoms, Respiratory studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Bifidobacterium longum101
BLU-5937022
Gefapixant022
Lactobacillus plantarum001
Indacaterol011
Glycopyrrolate011
Ascorbic Acid001
Montelukast001
Busulfan001

Coming up

1phase 3 study under way
3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Who these studies take

Of the 5 Signs and Symptoms, Respiratory studies recruiting now, 5 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
101 (20%)1 (20%)
184 (80%)4 (80%)
304 (80%)4 (80%)
404 (80%)4 (80%)
504 (80%)4 (80%)
655 (100%)5 (100%)
755 (100%)5 (100%)
855 (100%)5 (100%)

Across all 64 studies, recruiting or not: 45% stop at 75 or younger and 38% at 65; 28% take children; 6% are for women only and 0% for men only; 33% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Signs and Symptoms, Respiratory studies take

Of 18 interventional studies with no phase under Signs and Symptoms, Respiratory, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase12 mo5–26 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 64. Browse all 64 → or search them.